Gene therapy progress and prospects: Cancer gene therapy using tumour suppressor genes

Gene Therapy

Volumn 11, Issue 6, 2004, Pages 497-503

  McNeish, I A ^a   Bell, S J ^a   Lemoine, N R ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Cinical trial; p53; PTEN; Rb; Tumour suppressor gene

Indexed keywords

ADENOVIRUS VECTOR; AMINO ACID; ARF PROTEIN; CELL ADHESION MOLECULE; DOXORUBICIN; E1A PROTEIN; FLUOROURACIL; GEMCITABINE; INTERLEUKIN 24; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE; PLECTIN; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P107; PROTEIN P130; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P18; PROTEIN P21; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR SUPPRESSOR PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; VINCRISTINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER THERAPY; CHROMOSOME 10; CLINICAL STUDY; CLINICAL TRIAL; COLORECTAL CANCER; DOSE RESPONSE; DRUG TARGETING; GENE DELETION; GENE REPLACEMENT THERAPY; GENE TARGETING; GENE TRANSFER; GLIOMA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OVARY CARCINOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN MICROARRAY; PROTEIN TARGETING; RETINOBLASTOMA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS REPLICATION;

GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; NEOPLASMS;

ONYX;

EID: 1842529509     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302238     Document Type: Review

References (70)

1. Rosenwald A et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937-1947.
2. Khan J et al. Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks. Nat Med 2001; 7: 673-679.
3. Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther 2002; 9: 553-566.
4. Schuler M et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: Results of a multicenter phase II study. J Clin Oncol 2001; 19: 1750-1758.
5. Kuball J et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 2002; 20: 957-965.
6. Pagliaro LC et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: A phase I study of p53 gene therapy. J Clin Oncol 2003; 21: 2247-2253.
7. Lang FF et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: Biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
8. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003; 4: 415-422.
9. Reles A et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 2001; 7: 2984-2997.
10. Vousden KH, Lu X. Live or let die: The cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
11. Wolf BB et al. Defective cytochrome c-dependent caspase activation in ovarian cancer cell lines due to diminished or absent apoptotic protease activating factor-1 activity. J Biol Chem 2001; 276: 34244-34251.
12. de Vries A et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA 2002; 99: 2948-2953.
13. Bergamaschi D et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387-402.
14. Reid T et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: A phase I trial, Gene Therapy 2001; 8: 1618-1626.
15. Hamid O et al. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 1498-1504.
16. Vasey PA et al. Phase I trial of intraperitoneal injection of the E1B-55-kDa-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-1569.
17. Hecht JR et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003; 9: 555-561.
18. Mulvihill S et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial. Gene Therapy 2001; 8: 308-315.
19. Reid T et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-6079.
20. Dix BR et al. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001; 75: 5443-5447.
21. Ries SJ et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6: 1128-1133.
22. Edwards SJ et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002; 76: 12483-12490.
23. Flesken-Nikitin A et al. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63: 5459-3463.
24. Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2: 103-112.
25. Ip SM et al. pRb-expressing adenovirus Ad5-Rb attenuates the p53-induced apoptosis in cervical cancer cell lines. Eur J Cancer 2001; 37: 2475-2483.
26. Li D et al. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res 2002; 62: 4637-4644.
27. Zhang X et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis and caspasedependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res 2003; 63: 760-765.
28. Wills KN et al. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle alpha-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Therapy 2001; 8: 1847-1854.
29. Claudio PP et al. Mutations in the retinoblastoma-related gene RB2/p13O in lung tumors and suppression of tumor growth in vivo by retrovirus- mediated gene transfer. Cancer Res 2000; 60: 372-382.
30. Heise C et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med 2000; 6: 1134-1139.
31. Fueyo J et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
32. Bauerschmitz GJ et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270.
33. Fueyo J et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
34. Jakubczak JL et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003, 63: 1490-1499.
35. Johnson L et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
36. Branton PE, Roopchand DE. The role of adenovirus E4orf4 protein in viral replication and cell killing. Oncogene 2001; 20: 7855-7865.
37. Sharpless NE et al. Both products of the mouse Ink4a/Arf locus suppress melanoma formation in vivo. Oncogene 2003; 22: 5055-5059.
38. Modesitt SC et al. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001; 7: 1765-1772.
39. Turturro F et al. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p161NK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin's disease. Leukemia Lymphoma 2002; 43: 1323-1328.
40. Simon M et al. Conditional expression of the tumor suppressor p16 in a heterotopic glioblastoma model results in loss of pRB expression. J Neurooncol 2002; 60: 1-12.
41. Kawakami Y et al. Adenovirus-mediated p16 gene transfer changes the sensitivity to taxanes and Vinca alkaloids of human ovarian cancer cells. Anticancer Res 2001; 21: 2537-2545.
42. Hemmati PG et al. Adenovirus-mediated overexpression. of p14(ARF) induces p53 and Bax-independent apoptosis. Oncogene 2002; 21: 3149-3161.
43. Kuo ML et al. Arf induces p53-dependent and -independent antiproliferative genes. Cancer Res 2003; 63: 1046-1053.
44. Lu W et al. Expression of p14ARF overcomes tumor resistance to p53. Cancer Res 2002; 62: 1305-4310.
45. Saadatmandi N et al. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status. Cancer Gene Ther 2002; 9: 830-839.
46. Tango Y et al. Adenovirus-mediated p14ARF gene transfer cooperates with Ad5CMV-p53 to induce apoptosis in human cancer cells. Hum Gene Ther 2002; 13: 1373-1382.
47. Yang CT et al. Adenovirus-mediated p14(ARF) gene transfer in human mesothelioma cells. J Natl Cancer Inst 2000; 92: 636-641.
48. Deng X et al. Recombinant adenovirus-mediated p14(ARF) overexpression sensitizes human breast cancer cells to cisplatin. Biochem Biophys Res Commun 2002; 296: 792-798.
49. Weber HO et al. Human p14(ARF)-mediated cell cycle arrest strictly depends on intact p53 signaling pathways. Oncogene 2002; 21: 3207-3212.
50. Eymin B et al. Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 2001; 20: 1033-1041.
51. Fatyol K, Szalay AA. The p14ARF tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits HIF-1-mediated transcription. J Biol Chem 2001; 276: 28421-28429.
52. Karayan L et al. Human ARF protein interacts with topoisomerase I and stimulates its activity. Oncogene 2001; 20: 836-848.
53. Eymin B et al. p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice. Oncogene 2003; 22: 1822-1835.
54. Stahl JM et al. Loss of PTEN promotes tumor development in malignant melanoma. Cancer Res 2003; 63: 2881-2890.
55. Fernandez M, Eng C. The expanding role of PTEN in neoplasia: a molecule for all seasons? Clin Cancer Res 2002; 8: 1695-1698.
56. Huang H et al. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem 2001; 276: 38830-38836.
57. Yuan XJ, Whang YE. PTEN sensitizes prostate cancer cells to death receptor-mediated and drug-induced apoptosis through a FADD-dependent pathway. Oncogene 2002; 21: 319-327.
58. Davies MA et al. Adenoviral-mediated expression of MMAC/PTEN inhibits proliferation and metastasis of human prostate cancer cells. Clin Cancer Res 2002; 8: 1904-1914.
59. Tanaka M, Grossman HB. In vivo gene therapy of human bladder cancer with PTEN suppresses tumor growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Therapy 2003; 10: 1636-1642.
60. Huang J, Kontos CD. PTEN modulates vascular endothelial growth factor-mediated signaling and angiogeluc effects. J Biol Chem 2002; 277: 10760-10766.
61. Wen S et al. PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 2001; 98: 4622-4627.
62. Abe T et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res 2003; 63: 2300-2305.
63. Ekmekcioglu S et al. Down-regulated melanoma differentiation associated gene (mda-7) expression in human melanomas. Int J Cancer 2001; 94: 54-59.
64. Saeki T et al. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Ther 2000; 7: 2051-2057.
65. Mhashilkar AM et al. Melanoma differentiation associated gene-7 (mda-7): A novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 7: 271-282.
66. Saeki T et al. Inhibition of human lung cancer growth following adenovirus-mediated mda-7 gene expression in vivo. Oncogene 2002; 21: 4558-4566.
67. Pataer A et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239-2243.
68. Mhashilkar AM et al. MDA-7 negatively regulates the betacatenin and PI3K signaling pathways in breast and lung tumor cells. Mol Ther 2003; 8: 207-219.
69. Ramesh R et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105-5113.
70. Sellar GC et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34: 337-343.